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OBJECTIVES The aim of this study was to determine whether the use of amiodarone in patients with atrial
fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker.
BACKGROUND Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to
studies assessing the therapy’s use in the management of patients with ventricular arrhyth-
mias.
METHODS A study cohort of 8,770 patients age 65 years with a new diagnosis of AF was identified
from a provincewide database of Quebec residents with a myocardial infarction (MI) between
1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring
a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic
regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with
amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I
antiarrhythmic agents, beta-blockers, calcium channel blockers, and digoxin.
RESULTS Amiodarone use was associated with an increased risk of pacemaker insertion (OR: 2.14, 95%
confidence interval [CI]: 1.30 to 3.54). This effect was modified by gender, with a greater risk
in women versus men (OR: 3.86, 95% CI: 1.70 to 8.75 vs. OR: 1.52, 95% CI: 0.80 to 2.89).
Digoxin was the only other medication associated with an increased risk of pacemaker
insertion (OR: 1.78, 95% CI: 1.37 to 2.31).
CONCLUSIONS This study suggests that the use of amiodarone in elderly patients with AF and a previous MI
increases the risk of bradyarrhythmia requiring a permanent pacemaker. The finding of an
augmented risk of pacemaker insertion in elderly women receiving amiodarone requires
further investigation. (J Am Coll Cardiol 2003;41:249–54) © 2003 by the American
College of Cardiology Foundation
As the elderly population continues to expand, atrial fibril-
lation (AF) is becoming an increasingly common medical
condition. Approximately 85% of patients with AF are older
than 65 years (1), and the prevalence of AF can increase
from 2% in people age 60 to 69 years to 9% in people age 80
to 89 years (2,3). Atrial fibrillation has been shown to
quadruple the risk of stroke and double the risk of mortality
(2,4). Coronary artery disease is also a risk factor for AF.
The first Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries trial
(GUSTO-1) reported AF in 10% of 21,722 post-
myocardial infarction (MI) patients whose median age was
61 years (5).
One strategy for treating AF involves the use of antiar-
rhythmic medications to maintain sinus rhythm after spon-
taneous, pharmacologic, or electrical cardioversion. Alter-
native strategies focus on heart rate control and
anticoagulation (6). The goal of maintaining sinus rhythm is
to decrease the risks associated with AF (7). Other pre-
sumed benefits of rhythm control include improved exercise
tolerance, decreased symptoms, and improved quality of life.
A number of trials are investigating whether maintaining
sinus rhythm with antiarrhythmic medications decreases
mortality or improves quality of life (8–11). The Atrial
Fibrillation Follow-up Investigation of Rhythm Manage-
ment (AFFIRM) study (11) found no survival benefit of
rhythm control over rate control strategies in patients with
AF and at least one other risk factor for stroke or death.
Despite the potential benefits of antiarrhythmic therapy,
these agents can be associated with dangerous cardiovascular
side effects. Data on the use of sotalol for AF describe the
occurrence of heart rate slowing requiring permanent pace-
maker implantation (12,13). Using multivariate analysis,
previous MI and older age were associated with the greatest
risk of cardiac adverse events, most commonly brady-
arrhythmias (13). Recent studies suggest that amiodarone
may be more effective than sotalol in maintaining sinus
rhythm in patients with AF, with an increase in noncardiac
side effects but no increased risk of significant bradyarrhyth-
mias (14,15). Reports of amiodarone-induced severe brady-
cardia requiring permanent pacemaker are infrequent and
have been limited to studies assessing amiodarone’s efficacy
in the treatment of ventricular arrhythmias (16).
The objective of this study was to evaluate the risk of
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bradyarrhythmia requiring permanent pacemaker insertion
associated with the use of amiodarone to treat AF in
patients at high risk of severe bradycardia. The study was
therefore limited to elderly (65 years old) patients with
previous MI.
METHODS
Study population. A provincewide database of residents
having an acute myocardial infarction (AMI) between 1991
and 1999 in Quebec, Canada, was constructed by linking
the Quebec hospital discharge summary database (Med-
Echo) with the provincial physician and drug claims data-
base (Regie de l’Assurance Maladie du Quebec [RAMQ]),
using methods described previously (17). Patients were
included in the database if they were admitted to hospital
with a diagnosis of AMI (International Classification of
Disease 9 [ICD9] code 410) between 1991 and 1999 and
had no previous admission for an AMI (since 1985).
Follow-up information was available until the end of 1999.
This database included 113,012 patients.
From the database, 14,187 patients (12.6%) were identi-
fied as having been diagnosed with AF (ICD9 code 427.3,
427.31, or 427.32) during their initial admission for an
AMI, during any subsequent admission, or during any
subsequent inpatient or outpatient physician visit. After
patients with a previous diagnosis of AF (within one year
before the date of their index AMI) were excluded, there
remained 12,559 patients.
The time of entry into the study cohort (T  0) was
defined by the date of the first diagnosis of AF following (or
concurrent with) the date of index AMI. Inclusion in the
study cohort was limited to persons 65 years of age at the
time of diagnosis of AF (9,323 patients) in order to have
complete medication data for all patients (the RAMQ drug
claims database contains information for all individuals65
years of age).
Other exclusion criteria included previous pacemaker or
defibrillator insertion (231 patients), or ventricular arrhyth-
mia (356 patients) within one year before cohort entry.
Persons with previous pacemaker were excluded because
they would not be able to develop the outcome of interest
(i.e., heart block requiring pacemaker insertion). Persons
with previous ventricular arrhythmia or defibrillator were
excluded because they were likely to have already been
treated with antiarrhythmic medications before their diag-
nosis of AF. Persons who were diagnosed with a ventricular
arrhythmia only after their diagnosis of AF were not
excluded, but this information was recorded and adjusted
for in the analysis.
The final study cohort included 8,770 patients. All
subjects were followed until time of death, pacemaker
implantation, or December 31, 1999. The study was ap-
proved by the McGill University Faculty of Medicine
Institutional Review Board.
Cases. Cases consisted of patients who received a perma-
nent pacemaker during the follow-up period. Of a total of
485 subjects who received a pacemaker, eight subjects were
censored because they had undergone ablation of their
atrioventricular (AV) node within two weeks of their
permanent pacemaker insertion. The remaining 477 sub-
jects were retained as cases. The index date for each case was
defined as the date of permanent pacemaker implantation.
Controls. In a nested case-control design, four controls
were randomly selected from the risk set of each case,
defined by the cohort time axis (i.e., the number of days
from entry into the cohort to the index date of each case).
Controls were also matched according to the date (within a
six-month period) that each case had a permanent pace-
maker inserted in order to control for variations in medica-
tion use over time.
The index date for controls was defined according to the
time from cohort entry to the date of pacemaker insertion of
the respective case. Thus, the index date minus the AF
diagnosis date is the same for all five members of each set,
containing a case and its four controls.
Exposure assessment. Baseline information recorded for
all cohort patients included age, gender, and presence of
sinoatrial (SA) node dysfunction (ICD9 code 427.81) or
conduction disorder (ICD9 code 426.1 to 426.6) within two
years before cohort entry.
Any subsequent diagnosis of a ventricular arrhythmia
(ICD9 code 427.1, 427.4, or 427.5) during the study period
was recorded. Cases and controls were classified as having a
ventricular arrhythmia if this diagnosis was made before
their index date.
Details about exposure of cases and controls to various
cardiac medications were also recorded during the study
period. For each dispensed medication, information in-
cluded the date and duration of the prescription. Antiar-
rhythmic agents included amiodarone, sotalol, and class I
agents (disopyramide, flecainide, mexilitene, procainamide,
propafenone, and quinidine). Beta-blockers, calcium chan-
nel blocking agents (diltiazem and verapamil), and digoxin
were also included in the analysis.
The definition of exposure to a drug for both cases and
controls was the use of a medication immediately before the
index date of pacemaker insertion. It was assumed that
subjects took their medication from the date that it was
dispensed until the end of the duration of the prescription.
Abbreviations and Acronyms
AF  atrial fibrillation
AMI  acute myocardial infarction
AV  atrioventricular
CI  confidence interval
ICD9  International Classification of Disease 9
LV  left ventricular
MI  myocardial infarction
OR  odds ratio
RAMQ  Regie de l’Assurance Maladie du Quebec
SA  sinoatrial
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Because there may have been a lapse between the time a case
was admitted for pacemaker implantation and the actual
date of the procedure (index date), all study subjects were
defined as having been exposed to a medication if the date
of the last prescription (before index date) plus the duration
of the prescription plus seven days exceeded the index date.
Another factor taken into consideration was the half-life of
the medication, with amiodarone being the one with the
longest (30 days compared to 48 h for all other
medications). Thus it was decided a priori that subjects
would be defined as having been exposed to amiodarone if
the date of their last prescription plus the duration of the
prescription plus 30 days (instead of 7 days) exceeded the
index date.
A binary variable was created for each of the six medica-
tion groups (amiodarone, sotalol, class I agents, beta-
blockers, calcium channel blockers, and digoxin) to indicate
exposure or nonexposure. An additional ordinal variable was
created to account for the simultaneous use of beta-blockers,
calcium channel blockers, and digoxin.
Statistical analysis. Within the study cohort, a nested
case-control analysis was performed. For each binary inde-
pendent variable, chi-square tests, crude odds ratios (OR),
and 95% confidence intervals (CI) were estimated. A p value
0.05 was considered statistically significant. All statistical
analyses were performed using SAS Version 8 statistical
software package.
In order to identify possible confounders or modifiers of
the effect of the main exposure (amiodarone) on the
outcome, a series of analyses were performed with stratifi-
cation by every other binary variable in turn. Possible effect
modifiers, identified using Breslow-Day tests for homoge-
neity (18), and possible confounders, identified by compar-
ing Mantel-Haenzel and crude ORs, were subsequently
analyzed in regression models.
After satisfaction of the linearity assumption for contin-
uous and ordinal variables was confirmed, multivariable
conditional logistic regression was used to estimate ORs
(and 95% CIs) for pacemaker implantation. It was decided
a priori to adjust for the effects of age and gender regardless
of statistical significance. Starting from a model including
all variables (age, gender, baseline SA node dysfunction or
conduction disorder, ventricular arrhythmia, and exposure
to amiodarone, sotalol, class I antiarrhythmics, beta-
blockers, calcium channel blockers, and digoxin), nonsignif-
icant variables (other than age and gender) were sequentially
removed if the resultant model had improved Akaike
Information Criteria with a minimal decrease in likelihood
ratio, and without a significant change in ORs for remaining
variables. A separate but similar analysis was also performed
using an ordinal variable indicating the number of SA/AV
nodal suppressing medications (the sum of the three binary
variables for beta-blockers, calcium channel blockers, and
digoxin).
The multivariable regression analysis was repeated with
several modifications in definition of exposure to medica-
tions to determine whether there were any changes in the
effects observed. In particular, the definition of exposure to
amiodarone was modified to “date of last prescription plus
duration of prescription plus seven days (or 60 days, instead
of 30 days) exceeds index date.” Likewise, the definition of
exposure to other medications (such as digoxin) was mod-
ified to “date of last prescription plus duration of prescrip-
tion plus 14 days (or 60 days, instead of 7 days) exceeds
index date.”
RESULTS
Patient population. The study cohort included 8,770 pa-
tients, 477 (5.4%) of whom met criteria for definition as
cases. The 477 cases were matched (1:4) to 1,908 controls.
The mean age of cases and controls was 76.6 years, and
58.3% were men. Table 1 provides summary statistics. In
bivariate analysis, a history of SA node dysfunction or
conduction disorder, new ventricular arrhythmia, exposure
to amiodarone, and exposure to digoxin significantly in-
creased the odds of pacemaker implantation (Table 1). Only
one patient was exposed to both amiodarone and a class I
Table 1. Clinical Characteristics of Cases and Controls
All Subjects
n  2,385
Cases
n  477
Controls
n  1,908
Crude OR*
(95% CI)
p Value
(Chi-Squared)
Mean age 75.7 75.7 75.7
(SD) (6.7) (6.4) (6.7)
Age (% 75 yrs) 46.9 48.9 46.4 1.10 (0.90–1.35) 0.36
Men (%) 58.3 60.6 57.8 1.12 (0.92–1.38) 0.26
SA node dysfunction or conduction disorder (%) 2.8 5.9 2.0 3.07 (1.86–5.05)  0.0001
Ventricular arrhythmia (%) 8.9 14.7 7.4 2.14 (1.58–2.90)  0.0001
Medications
Amiodarone (%) 3.2 6.1 2.5 2.56 (1.60–4.12)  0.0001
Sotalol (%) 4.0 5.0 3.7 1.37 (0.85–2.20) 0.19
Class I agents (%) 2.4 2.5 2.4 1.07 (0.56–2.04) 0.84
Beta-blockers† (%) 9.7 9.4 9.8 0.96 (0.68–1.35) 0.81
Calcium blockers (%) 5.2 5.2 5.1 1.02 (0.65–1.60) 0.93
Digoxin (%) 17.5 24.5 15.7 1.74 (1.37–2.22)  0.0001
*Unadjusted odds ratios (ORs) for bradyarrhythmia requiring permanent pacemaker implantation estimated in bivariate analysis using chi-square tests. †Excluding sotalol.
CI  confidence interval; SA  sinodtrial.
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agent, one patient was exposed to both sotalol and a class I
agent, and no one was exposed to both sotalol and amio-
darone.
Risk of pacemaker insertion associated with use of
amiodarone. After adjusting for age, gender, SA node
dysfunction or conduction disorder, ventricular arrhythmia,
and digoxin exposure (as both a negative chronotrope and a
marker of left ventricular [LV] dysfunction), amiodarone
use was associated with an increased risk of pacemaker
implantation (OR: 2.14, 95% CI: 1.30 to 3.54) (Table 2).
The final model adjusted for the effects of age and gender
despite lack of statistical significance, as was decided a
priori. The variables ventricular arrhythmia and digoxin
were adjusted because they were identified as confounders of
the effect of amiodarone. The variable baseline SA node
dysfunction or conduction disorder, although not a con-
founder, was included in the final model because it was a
significant independent predictor of pacemaker insertion.
All other nonsignificant variables (sotalol, class I antiar-
rhythmics, beta-blockers, and calcium channel blockers)
were sequentially removed from the model without signif-
icant change in ORs for remaining variables.
The number of SA/AV nodal suppressing medications
was not found to be an independent predictor of pacemaker
insertion after adjustment for digoxin use (OR: 0.93, 95%
CI: 0.69 to 1.25).
Results were not significantly changed when the multi-
variable regression analysis was repeated using several mod-
ifications in the definition of exposure to amiodarone and
other medications.
Modification of the effect of amiodarone by gender. Gen-
der was the only variable identified as a possible effect
modifier of the relationship between amiodarone use and
the subsequent need for a permanent pacemaker. Inclusion
of an interaction term for amiodarone and gender in the
final model suggests that pacemaker insertion is more
frequent in women receiving amiodarone (OR: 3.86, 95%
CI: 1.70 to 8.75 vs. OR: 1.52, 95% CI: 0.80 to 2.89).
Although the interaction term for amiodarone and gender
(OR: 0.39, 95% CI: 0.14 to 1.11) was not statistically
significant, the magnitude of the effect suggests the possi-
bility of modification of the effect of amiodarone by gender.
For this reason, a second final model with this interaction
term is presented in Table 2.
Risk of pacemaker insertion associated with use of
sotalol. Although there was a trend toward an association
between sotalol and pacemaker implantation, the magnitude
of the effect was small and was not statistically significant
(OR: 1.30, 95% CI: 0.79 to 2.14, p  0.29).
DISCUSSION
The results of this study support the initial hypothesis that
elderly patients post-AMI treated with amiodarone for AF
are at increased risk of bradyarrhythmia requiring a perma-
nent pacemaker. These patients were more than twice as
likely to require a permanent pacemaker, even after adjust-
ing for time since AF, calendar time, age, gender, SA node
dysfunction or conduction disorder, ventricular arrhythmia,
and exposure to antiarrhythmic and rate control agents. Of
note, there was no significant association between the use of
sotalol and permanent pacemaker insertion (adjusted OR:
1.30, 95% CI: 0.79 to 2.14, p 0.29). Digoxin was the only
other medication that was associated with a significant
increase in odds of requiring a permanent pacemaker (OR:
1.78, 95% CI: 1.37 to 2.31). This study also demonstrated
a strong association between prior SA node dysfunction or
conduction disorder and the need for a permanent pace-
maker (Table 2).
Exposure to amiodarone was associated with a greater
risk of pacemaker implantation in women. This finding may
be related to the tendency to treat women with the same
doses of amiodarone as men, despite a relatively smaller
body size, weight, and volume of distribution.
The absence of previous reports describing bradyarrhyth-
mia requiring permanent pacemaker insertion during ami-
odarone therapy for AF may be due to the study populations
and their risk of bradyarrhythmias. The Canadian Trial of
Atrial Fibrillation, for example, reported a relatively low
incidence of serious bradyarrhythmias (3%), with no differ-
ence between groups randomized to amiodarone versus
sotalol or propafenone. The study patients had a low
Table 2. Adjusted Risk of Bradyarrhythmia Requiring a Permanent Pacemaker
Variable
Final Model Final Model With Interaction*
OR† 95% CI p Value OR† 95% CI p Value
Age 1.01 (0.99–1.02) 0.51 1.01 (0.99–1.02) 0.47
Male gender 1.12 (0.90–1.38) 0.31 1.16 (0.93–1.44) 0.18
SA node dysfunction/conduction disorder 3.12 (1.87–5.22)  0.0001 3.32 (1.87–5.24)  0.0001
Ventricular 2.09 (1.53–2.87)  0.0001 2.09 (1.52–2.86)  0.0001
Arrhythmia
Amiodarone 2.14 (1.30–3.54) 0.0030 3.86 (1.70–8.75) 0.0012
Digoxin 1.78 (1.37–2.31)  0.0001 1.79 (1.38–2.32)  0.0001
AmioSex‡ 0.39 (0.14–1.11) 0.0782
*Results of multivariable conditional logistic regression in a model including an interaction term to account for possible modification of the effect of amiodarone by gender. †Odds
ratios are adjusted for all other variables in the model (by multivariable regression analysis) and are adjusted for calendar time and time since diagnosis of AF (by study design).
‡Variable for interaction between amiodarone and gender.
Abbreviations as in Table 1.
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incidence of coronary disease (19%) and a mean age of 65
years (14). Given that elderly patients with prior MI are at
greatest risk for bradyarrhythmias during antiarrhythmic
drug therapy for AF (13), the current study was designed to
include only elderly patients (65 years old) with AF
post-MI. In this higher risk population, amiodarone was
found to increase the risk of bradyarrhythmia requiring
permanent pacemaker insertion.
We found no significant effect of sotalol on the risk of
pacemaker insertion despite results of previous studies on
the risk of in-hospital initiation of antiarrhythmic drugs for
patients with AF. In one study (12), initiation of sotalol was
associated with significant bradycardia in 20 of 120 patients
(16.7%), requiring permanent pacemaker in three patients
(2.5%) and dose reduction in most of the other patients.
The episodes of bradycardia occurred soon after initiation of
sotalol; 50% by day 1 and 90% by day 3 after initiation. In
another study (13), bradyarrhythmias occurred in eight of
72 patients (11.1%) started on sotalol and one of 25 patients
(4%) started on amiodarone. It is possible that the number
of patients on sotalol in our study was not large enough to
detect a statistically significant increased risk of pacemaker
insertion. Our study may have also underestimated the use
of sotalol in cases of pacemaker insertion if patients started
sotalol in hospital and had a pacemaker placed before filling
their prescription. An important difference between amio-
darone and sotalol is the much longer half-life of amioda-
rone (30 days vs. 24 h). When bradycardia complicates
sotalol therapy, permanent pacemaker insertion is often
avoided by reducing the dosage. When severe bradyarrhyth-
mias complicate amiodarone therapy, they may be less likely
to resolve soon after cessation of amiodarone.
The strong association between a previous diagnosis of
SA node dysfunction or conduction disorder and the risk of
pacemaker insertion is not surprising. Use of amiodarone in
patients with SA node dysfunction or conduction disorder
carries a high risk of severe bradyarrhythmia.
The finding that a diagnosis of ventricular arrhythmia
was strongly associated with pacemaker insertion, even after
adjustment for other variables, including amiodarone, may
in part be related to a tendency for these patients to be
treated with higher doses of amiodarone.
Study limitations. This is a retrospective analysis of data
derived from administrative databases. Although such da-
tabases allow for access to a wide variety of data on very
large numbers of patients, certain clinical information is not
available. We were unable to directly adjust for LV dysfunc-
tion in our study. However, by adjusting for digoxin use, we
at least partially adjusted for LV dysfunction.
Identification of patients with AF may have been incom-
plete because some patients may have had AF without ever
having a diagnosis recorded. However, we found a diagnosis
of AF in 12.6% of the 113,012 post-AMI patients in our
database, which is in keeping with results of previous studies
(5). Furthermore, even if the identification of patients with
AF was incomplete, this is unlikely to have introduced
selection bias because identification of AF was independent
of future pacemaker insertion.
Although drug claims data have been found to be reliable
(19), medication exposure data are limited by the assump-
tion that dispensed medication is consumed until the end of
the duration of the prescription. Given that the data
represent filled prescriptions as opposed to written prescrip-
tions, patients are more likely to be compliant. However, the
effect of noncompliance with supplied medications would be
nondifferential misclassification of exposure in our study
that would make our result a conservative estimate (biased
towards the null) of the true effect of amiodarone.
Conclusions. This study suggests that the use of amioda-
rone in elderly patients with AF and a previous MI increases
the risk of bradyarrhythmia requiring a permanent pace-
maker. The finding that the risk of bradyarrhythmia asso-
ciated with amiodarone use is greater in women than in men
requires further investigation.
Acknowledgment
We would like to thank Hugues Richard for statistical
programming expertise.
Reprint requests and correspondence: Dr. Vidal Essebag,
3600 Parc Avenue #1203, Montreal, Quebec H2X 3R2, Canada.
E-mail: vidal.essebag@mail.mcgill.ca.
REFERENCES
1. Feinberg WM, Blacksheir JL, Laupacis A, et al. Prevalence, age
distribution and gender of patients with atrial fibrillation: analysis and
implications. Arch Intern Med 1995;155:469–73.
2. Aronow WS. Management of the older person with atrial fibrillation.
J Am Geriatr Soc 1999;47:740–8.
3. Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural
history of atrial fibrillation: clinical implications. J Am Coll Cardiol
2001;37:371–8.
4. Laupacis A, Cuddy TE. Prognosis of individuals with atrial fibrilla-
tion. Can J Cardiol 1996;12 Suppl A:14A–6A.
5. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United
States in the management of acute myocardial infarction. N Engl
J Med 1995;333:565–72.
6. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation: an
evaluation of drug therapy, electrical modalities and therapeutic
considerations. Drugs 1994;48:354–71.
7. Levy S, Breithardt G, Campbell RW, et al. Atrial fibrillation: current
knowledge and recommendations for management. Working Group
on Arrhythmias of the European Society of Cardiology. Eur Heart J
1998;19:1294–320.
8. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines
for the management of patients with atrial fibrillation: executive
summary: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the Euro-
pean Society of Cardiology Committee for Practice Guidelines and
Policy Conferences (Committee to Develop Guidelines for the Man-
agement of Patients With Atrial Fibrillation). J Am Coll Cardiol
2001;38:1231–65.
9. Falk RH. Atrial fibrillation. N Engl J Med 2001;344:1067–78.
10. Connolly SJ. Appropriate outcome measures in trials evaluating
treatment of atrial fibrillation. Am Heart J 2000;139:752–60.
11. The Planning and Steering Committees of the AFFIRM Study for the
NHLBI AFFIRM Investigators. Atrial fibrillation follow-up investi-
gation of rhythm management—the AFFIRM study design. Am J
Cardiol 1997;79:1198–202.
253JACC Vol. 41, No. 2, 2003 Essebag et al.
January 15, 2003:249–54 Amiodarone and Risk of Permanent Pacemaker
12. Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission
for initiation of antiarrhythmic therapy with sotalol for atrial fibrilla-
tion required? J Am Coll Cardiol 1998;32:169–76.
13. Maisel WH, Kuntz KM, Reinhold SC, et al. Risk of initiating
antiarrhythmic drug therapy for atrial fibrillation in patients admitted
to a university hospital. Ann Intern Med 1997;127:281–4.
14. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence
of atrial fibrillation. N Engl J Med 2000;342:913–20.
15. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low dose
amiodarone and sotalol in the treatment of recurrent, symptomatic
atrial fibrillation: a comparative, placebo controlled study. Heart
2000;84:251–7.
16. Connolly SJ. Evidence-based analysis of amiodarone efficacy and
safety. Circulation 1999;100:2025–34.
17. Pilote L, Lavoie F, Ho V, et al. Changes in the treatment and
outcomes of acute myocardial infarction in Quebec, 1988–1995.
CMAJ 2000;163:31–6.
18. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol. 1:
The Analysis of Case-Control Studies. Lyon: International Agency for
Research on Cancer, 1980, 142.
19. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims
databases in pharmacoepidemiological research: the accuracy and
comprehensiveness of the prescription claims database in Quebec.
J Clin Epidemiol 1995;48:999–1009.
254 Essebag et al. JACC Vol. 41, No. 2, 2003
Amiodarone and Risk of Permanent Pacemaker January 15, 2003:249–54
